Laden…
2-amino-5-phenyl-1,3-oxazol-4-one
Pemoline is a central nervous system stimulant from the class of oxazolidinones, primarily acting as a dopamine reuptake inhibitor. It was previously used for the treatment of ADHD and narcolepsy but has been restricted or withdrawn from the market in many countries due to potential liver damage. The substance shows a lower potential for dependence than classical amphetamines but still carries risks with long-term use.
Class
Oxazolidinone
Pharmacological context
Mechanism
Pemoline wirkt als Dopamin-Wiederaufnahmehemmer, wodurch die...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: 2-amino-5-phenyl-2-oxazolin-4-one
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der Noradrenalintransporter (NET) ist ein Monoamintransporter, der Noradrenalin aus dem synaptischen Spalt zurücktransportiert. Er wird von verschiedenen Stimulants und Antidepressiva beeinflusst.
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulants und spielt eine Schlüsselrolle im Belohnungssystem.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class. Limited data — interpret profile with caution.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Pemoline wirkt als Dopamin-Wiederaufnahmehemmer, wodurch die Verfügbarkeit von Dopamin im synaptischen Spalt erhöht wird.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 10–20 mg
Total duration 6–8 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 5–10 mg |
| Reported | 10–20 mg |
| Strong | 20–40 mg |
Oral
Onset
1–2 hours
Peak
3–4 hours
Total duration
6–8 hours
After effects
2–4 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Potenzielle Leberschäden und andere Nebenwirkungen.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.